Scholarlink

<p>The best conditioning for hematopoietic stem cell transplantation (HSCT) in acute lymphoblastic leukemia is debated. We analyzed 178 adults undergoing HSCT with total body irradiation (TBI) or chemotherapy conditioning regimens for B-cell leukemia in complete remission 1 (CR1). Both TBI and chemotherapy regimens showed comparable overall survival (OS) and leukemia-free survival (LFS). However, TBI had a trend of reduced relapse (HR 0.56, <i>P</i> = 0.064) but higher non-relapse mortality (NRM, HR 3.23, <i>P</i> = 0.072) due to increased grade 3 to 4 graft-versus-host disease (22.8% vs. 8.8%, <i>P</i> = 0.023). The key factor affecting survival was minimal residual disease (MRD) after three chemotherapy cycles (OS <i>P</i> = 0.004, LFS <i>P</i> = 0.006). In MRD-negative patients, both regimens gave similar LFS and cumulative incidence of relapse (CIR) irrespective of whether the transplantation was allogeneic (allo-HSCT) or autologous (auto-HSCT), but the allo-HSCT group had a lower OS due to higher NRM (5.3% vs. 20.6%, <i>P</i> = 0.020). For MRD-positive patients, TBI was superior in LFS (71.9% vs. 43.9%, <i>P</i> = 0.017) and relapse rate (18.5% vs. 48.7%, <i>P</i> = 0.006). Our research indicates the choice between TBI and non-TBI should be based on MRD after three chemotherapy cycles.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Total body irradiation versus chemotherapy myeloablative conditioning in B-cell acute lymphoblastic leukaemia patients with first complete remission

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月24日

查看全文
  • Mengnan Lv,
  • Yi He,
  • Donglin Yang,
  • Qiaoling Ma,
  • Aiming Pang,
  • Weihua Zhai,
  • Jialin Wei,
  • Xin Chen,
  • Sizhou Feng,
  • Mingzhe Han,
  • Erlie Jiang,
  • Rongli Zhang

摘要

The best conditioning for hematopoietic stem cell transplantation (HSCT) in acute lymphoblastic leukemia is debated. We analyzed 178 adults undergoing HSCT with total body irradiation (TBI) or chemotherapy conditioning regimens for B-cell leukemia in complete remission 1 (CR1). Both TBI and chemotherapy regimens showed comparable overall survival (OS) and leukemia-free survival (LFS). However, TBI had a trend of reduced relapse (HR 0.56, P = 0.064) but higher non-relapse mortality (NRM, HR 3.23, P = 0.072) due to increased grade 3 to 4 graft-versus-host disease (22.8% vs. 8.8%, P = 0.023). The key factor affecting survival was minimal residual disease (MRD) after three chemotherapy cycles (OS P = 0.004, LFS P = 0.006). In MRD-negative patients, both regimens gave similar LFS and cumulative incidence of relapse (CIR) irrespective of whether the transplantation was allogeneic (allo-HSCT) or autologous (auto-HSCT), but the allo-HSCT group had a lower OS due to higher NRM (5.3% vs. 20.6%, P = 0.020). For MRD-positive patients, TBI was superior in LFS (71.9% vs. 43.9%, P = 0.017) and relapse rate (18.5% vs. 48.7%, P = 0.006). Our research indicates the choice between TBI and non-TBI should be based on MRD after three chemotherapy cycles.